Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer
November 01 2022 - 4:05PM
Business Wire
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics (EPBs), today
announced the appointment of Daniel O’Connor as Chief Executive
Officer.
“On behalf of the board of directors and management team, I
would like to welcome Dan to Ambrx. I very much look forward to
working with him to execute on Ambrx’s new strategic direction,”
said Katrin Rupalla, Chair of Ambrx’s Board of Directors. “Dan is
the ideal candidate for the role of CEO, given his extensive
leadership experience in oncology drug development, strategic
partnership formation, and streamlining operations within the
biotech industry. I would also like to thank Kate Hermans, our
interim CEO and board member, for her hard work, dedication, and
leadership over the past several months to reprioritize Ambrx’s
development pipeline.”
"I am thrilled by the opportunity to lead Ambrx as the company
focuses on the development of ARX517, potentially the first
PSMA-targeting ADC therapy for prostate cancer,” said Daniel
O’Connor, chief executive officer of Ambrx. “Ambrx’s proprietary
EPB platform enables us to produce biologic product candidates with
highly stable, site-specific conjugation, thereby overcoming the
inherent limitations of conventional drug conjugation approaches.
This has the potential to play a key role in changing the current
treatment paradigm for cancer patients. I look forward to working
together with the Ambrx management team to bring the promise of
Ambrx’s technology to cancer patients currently underserved by the
standard of care.”
Mr. O’Connor has over 23 years of executive experience and
leadership in all aspects of the biopharmaceutical industry,
including CEO leadership of two public oncology-focused companies,
OncoSec Medical and Advaxis, Inc., as well as C-Suite leadership
roles at ImClone Systems, Bracco Diagnostics, and PharmaNet, Inc.
(today, Syneos Health). He has a proven record of accomplishment in
oncology drug development, with a focus on business strategy,
clinical execution, product development, business transformation
and corporate development. He has overseen the successful
initiation of several early phase oncology clinical trials,
including combination trials with several different FDA approved
checkpoint inhibitors. Additionally, he has led numerous life
science licensing transactions and drug development collaborations
with major pharmaceutical companies and has raised hundreds of
millions in the capital marketplace. Mr. O’Connor earned a J.D.
from the Dickinson School of Law of Pennsylvania State University
and a B.A. from Boston University.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs) and other engineered therapies to
modulate the immune system. Ambrx is advancing a focused portfolio
of clinical and preclinical programs designed to optimize efficacy
and safety in multiple cancer indications, including its lead
product candidate ARX517, a prostate-specific membrane antigen
(PSMA) targeting ADC. In addition, Ambrx has clinical
collaborations with multiple partners on drug candidates generated
using Ambrx technology. For more information, please visit
www.ambrx.com.
Forward-Looking Statements
This press release includes certain “forward-looking statements”
intended to qualify for the “safe harbor” from liability
established by the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements may be identified by
the words “anticipate,” believe,” “estimate,” “expect,” “intend,”
“plan,” “project,” “may,” “will,” “could,” “should,” “seek,”
“potential” and similar expressions, and include, without
limitation, express or implied statements regarding Ambrx’s beliefs
and expectations regarding the advancement and potential benefits
of its product candidates, clinical development and strategic
plans, the expected benefits of Ambrx’s reprioritization, the
timing of program updates and milestones related to its product
candidates and Mr. O’Connor’s anticipated contributions.
Forward-looking statements are based on Ambrx’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, those
risks and uncertainties associated with: the continuing impact of
the COVID-19 pandemic and other public health-related risks and
events on Ambrx’s business, operations, strategy, goals and
anticipated milestones; Ambrx’s ability to execute on its strategy
including with respect to the timing of its R&D efforts,
initiation of clinical trials and other anticipated milestones;
risks associated with development of novel therapeutics, including
potential delays in clinical trials and regulatory submissions and
the fact that future clinical trial results may not be consistent
with preliminary results or results from prior preclinical studies
or clinical trials; Ambrx’s ability to fund operations as
anticipated; and the additional risks and uncertainties set forth
more fully under the caption “Risk Factors” in Ambrx’s Annual
Report on Form 20-F filed with the United States Securities and
Exchange Commission (SEC) on April 26, 2022, and elsewhere in
Ambrx’s filings and reports with the SEC. Forward-looking
statements contained in this press release are made as of this
date, and Ambrx undertakes no duty to publicly update or revise any
forward looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221101006251/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com MEDIA Gwen Schanker Account Supervisor
LifeSci Communications 269-921-3607 media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Apr 2023 to Apr 2024